Methods for the preparation of hybridomas producing lymphadenopa

Details Methods for the preparation of hybridomas producing lymphadenopa Methods for the preparation of hybridomas producing lymphadenopa

1994-09-27

1997-03-11

Nucker, Christine M.

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using tissue cell culture to make a protein or polypeptide

53038835, 530412, 530413, 4242081, C12P 2104, C12P 2108, C07K 1600, A23J 100

Patent

active

056100353

ABSTRACT:
A novel human retrovirus which is the aetiological agent of acquired immune deficiency syndrome (AIDS), designated lymphadenopathy-associated virus (LAV), was isolated from the lymph nodes of a patient suffering from generalized persistant lymphadenopathy. LAV displays a tropism for CD4.sup.+ lymphocytes, a Mg.sup.2+ -dependent reverse transcriptase (RT) activity, a density of 1.16-1.17 as determined by sucrose gradient centrifugation, a particle diameter of 139 nm, and a p25 antigen that is immunologically distinct from the HTLV-I/II p24 protein. Radioimmunoprecipitation analysis (RIPA) of .sup.35 S-cysteine-labeled viral or cellular lysates employing patient antisera resulted in the identification of a viral antigen having a molecular weight of 110 kDa. Endoglycosidase treatment of this antigen produces a protein with a molecular weight of 90 kDa. Methods are disclosed for the preparation of hybridomas producing LAV gp110-specific monoclonal antibodies (Mabs). Methods are also disclosed employing these MAbs in the purification of the LAV envelope glycoprotein, gp110.

REFERENCES:
patent: 4520113 (1985-05-01), Gallo et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4716102 (1987-12-01), Levy
patent: 4725669 (1988-02-01), Essex et al.
Goodenow et al., 1989, "HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions", J. Acquir. Immune Defic. Syndr. 2(4):344-52.
Wolfs et al., 1990, "Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous", Proc. Natl. Acad. Sci. USA 87(24):9938-42.
Watkins, et al., 1993, "Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways", J. Virol. 67(12):7493-7500.
Geysen et al., 1988, "Cognitive features of continuous antigenic determinants", J. Molec. Recog. 1:33-41.
Sarngadharan et al., 1985, "Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection", Cancer Res. 45:4574s-4577s.
Schneider et al., 1982, "A one-step purification of membrane proteins using a high efficiency immunomatrix", J. Biol. Chem. 257(18):10766-10769.
Kitchen et al, "Aetiology of AIDS--Antibodies to Human T-Cell Leukaemia Virus (Type III) in Haemophiliacs," Nature, 312, 367-369 (1984).
Essex et al., "Antibodies to Cell Membrane Antigens Associated with Human T-Cell Leukemia Virus in Patients with AIDS," Science, 220, 859-862 (1983).
Dreesman et al., "Antibody to Hepatitis B Surface Antigen After a Single Inoculation of Uncoupled Synthetic HBsAq Peptides," Nature, 295, 158-160 (1982).
Scheupbach et al., "Serological Analysis of a Subgroup of Human T-Lymphotropic Retroviruses (HTLV-III) Associated with AIDS," Science, 224, 503-505 (1984).
Kalyanaraman et al., "Antibodies to the Core Protein of Lymphadenopathy-Associated Virus (LAV) in Patients with AIDS," Science, 225, 321-323 (1984).
Robey et al., "Characterization of Envelope and Core Structural Gene Products of HTLV-III with Sera from AIDS Patients," Science, 228, 593-595 (1985).
Allan et al., "Major Glycoprotein Antigens That Induce Antibodies In AIDS Patients Are Encoded by HTLV-III," Science, 228, 1091-1094 (1985).
Crowl et al., Chemical Abstracts, 103, p. 190, No. 154983e (1985).
Montagnier et al., Chemical Abstracts, 103, p. 263, No. 34641v (1985).
Weiss et al., "Neutralization of Human T-Lymphotropic Virus Type III by Sera of AIDS and AIDS-Risk Patients," Nature, 316, 69-72 (1985).
Barin et al., "Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients," Science, 228, 1094-1096 (1985).
Wain-Hobson et al., "Nucleotide Sequence of the AIDS Virus, LAV," Cell, 40, 9-17 (1985).
Muesing et al., "Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus," Nature, 313, 450-458 (1985).
Schneider et al., Chemical Abstracts, 103, p. 430, No. 52370k (1985).
Sarnqadharan et al., Chemical Abstracts, 103, p. 551, No. 121329t (1985).
Alizon et al., "Molecular Cloning of Lymphadenopathy-Associated Virus," Nature, 312, 757-760 (1984).
Chang et al., "An HTLV-III Peptide Produced by Recombinant DNA is Immunoreactive with Sera from Patients with AIDS," Nature, 315, 151-154 (1985).
Chang et al., "Detection of Antibodies to Human T-Cell Lymphotropic Virus-III (HTLV-III) with an Immunoassay Employing a Recombinant Escherichia coli Derived Viral Antigenic Peptide," Biotechnology, 3, 905-909 (1985).
Schneider et al. "A Glycopolypeptide (qp 100) is the Main Antigen Detected by HTLV-III Antisera," Med. Microbiol. Immunol., 174, 35-42 (1985).
Allain et al., "Serological Markers in Early Stages of Human Immunodeficiency Virus Infection in Haemophiliacs," The Lancet, 2(8518), pp. 1233-1236 (1986).
Rasheed et al., "Virus-Neutralizing Activity, Serologic Heterogeneity, and Retrovirus Isolation From Homosexual Men in the Los Angeles Area," Virology, 150, pp. 1-9 (1986).
Montagnier et al., "Identification and Antigenicity of the Major Envelope Glycoprotein of Lymphadenopathy-Associated Virus," Virology, 144, pp. 283-289 (1985).
Gallo et al., "The Chronology of AIDS Research," Nature, 326, pp. 435-436 (1987).
Montagnier et al., "The AIDS Virus: Structure and Variation," in AIDS: The Safety of Blood and Blood Products, Petricciani et al., eds., pp. 1-10 (World Health Organization, John Wiley& Sons, 1987).
Clavel et al., "Deficient LAV.sub.1 Neutralising Capacity of Sera From Patients With AIDS or Related Syndromes," The Lancet, pp. 879-880 (Apr., 1985).
Brucker et al., "HIV-2 Infection in Two Homosexual Men in France," The Lancet, p. 223 (Jan., 1987).
Coffin et al., "Human Immunodeficiency Viruses," Science, 232, p. 697 (1986).
Biotechnol. Newswatch, vol. 5, p. 3, Abstract No. 03-10-003226 (1985).

Affiliated with

Also associated with

Rating

Methods for the preparation of hybridomas producing lymphadenopa does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the preparation of hybridomas producing lymphadenopa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the preparation of hybridomas producing lymphadenopa will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-442564